Skip to content

VIFU (Visual Functioning in Uveitis patints) Psychometric properties of the 25-Item National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) in patients with autoimmune uveitis

VIFU (Visual Functioning in Uveitis patints) Psychometric properties of the 25-Item National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) in patients with autoimmune uveitis - VIFU

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON29732
Enrollment
50
Registered
2006-08-24
Start date
2006-08-01
Completion date
Unknown
Last updated
2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arthritis of the eye autoimmune ocular inflammation

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Men and women *18 years with non-infectious uveitis due to one of the following causes: sarcoidosis, intermediate uveitis, Behcet's syndrome, idiopathic retinal vasculitis, birdshot chorioretinopathy, Vogt-Koyanaki-Harada disease or sympathetic ophthalmia, who meet the SUN criteria for acute uveitis. 2. Men and women *18 years with non-infectious uveitis due to one of the following causes: sarcoidosis, intermediate uveitis, Behcet's syndrome, idiopathic retinal vasculitis, birdshot chorioretinopathy, Vogt-Koyanaki-Harada disease or sympathetic ophthalmia, who meet the SUN criteria for chronic uveitis.

Exclusion criteria

Exclusion criteria: Age

Design outcomes

Primary

MeasureTime frame
content validity scale structure internal consistency (cronbach alpha) test- retest reliability (interclass correlation coefficient) construct validity responsiveness (paragraph 7.4 protocol)

Secondary

MeasureTime frame
composite score NEI-VFQ 25 subscale scores NEI-VFQ 25 (paragraph 7.5 protocol)

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)